1 Classification
Retinoblastoma is commonly classified by the number of eyes involved, whether the disease is inherited, and whether the tumor remains confined to the eye. These categories help guide prognosis, genetic counseling, and treatment selection.
1.1 Unilateral retinoblastoma
Unilateral retinoblastoma affects only one eye and is the more frequent presentation overall. It is often detected later than bilateral disease because the unaffected eye may preserve normal vision, making early signs less obvious to caregivers.
1.2 Bilateral retinoblastoma
Bilateral retinoblastoma involves both eyes and is more strongly associated with inherited genetic changes. It is usually diagnosed at a younger age and may present with different tumor sizes or stages in each eye.
1.3 Hereditary retinoblastoma
Hereditary retinoblastoma arises in individuals who carry a predisposing change in the RB1 gene. This form may be passed through a family or occur as a new mutation, and it increases the likelihood of tumors in both eyes as well as later tumors outside the eye.
1.4 Non-hereditary retinoblastoma
Non-hereditary retinoblastoma results from genetic changes acquired only in the tumor cells. It is typically limited to one eye and does not imply the same inherited risk to relatives or future children.
2 Causes and risk factors
The main cause of retinoblastoma is disruption of normal cell-cycle control in retinal cells. Risk is influenced by inherited predisposition, spontaneous mutations, and family history.
2.1 RB1 gene mutations
The RB1 gene encodes a tumor suppressor protein that helps regulate cell division. When both copies of this gene are inactivated in a retinal precursor cell, uncontrolled growth can occur and lead to retinoblastoma.
2.2 Inherited predisposition
An inherited RB1 alteration creates a predisposition to early tumor formation. Children with this predisposition are at increased risk of developing retinoblastoma, especially in both eyes, and may also face a lifelong risk of other cancers.
2.3 Somatic genetic changes
Somatic mutations arise after conception and are confined to tumor tissue. In retinoblastoma, two such acquired genetic hits can be sufficient to trigger malignant transformation in a retinal cell.
2.4 Family history
A family history of retinoblastoma suggests the possibility of an inherited form, even when the affected relative had only one eye involved. Family history is therefore important in assessing risk and planning screening for children.
3 Pathophysiology
Retinoblastoma develops from immature retinal cells that escape normal growth regulation. Its behavior is shaped by the timing of genetic damage, the cellular origin of the tumor, and its routes of extension within and beyond the eye.
3.1 Retinal cell origin
The tumor arises from retinal precursor cells during early childhood, a period when the retina is still developing. These cells retain enough proliferative capacity that loss of tumor suppressor function can rapidly drive neoplastic growth.
3.2 Tumor development
Early lesions may remain microscopic before becoming visible as an intraocular mass. As the tumor enlarges, it can disrupt the retina, block the visual axis, and produce characteristic clinical signs such as leukocoria.
3.3 Genetic mechanisms
The classic model involves inactivation of both RB1 alleles in a single retinal cell. Additional genetic and epigenetic changes may influence tumor aggressiveness, treatment response, and the tendency to spread.
3.4 Pattern of spread
Retinoblastoma usually begins within the eye but can extend into the vitreous, subretinal space, optic nerve, and orbit. In advanced cases, tumor cells may spread through lymphatic or hematogenous routes to distant sites.
4 Signs and symptoms
Clinical presentation depends on tumor size, location, and whether one or both eyes are affected. Many cases are first noticed by caregivers because the abnormal appearance of the pupil or a change in eye alignment is visible in photographs or ordinary lighting.
4.1 Leukocoria
Leukocoria is a white pupillary reflex and is one of the most common early signs. It may be seen in flash photographs or when light reflects oddly from the pupil.
4.2 Strabismus
Strabismus, or misalignment of the eyes, can occur when the tumor interferes with normal vision. The child may appear to have one eye turning inward, outward, upward, or downward.
4.3 Visual impairment
Reduced vision may be subtle in young children and can present as poor fixation, clumsiness, or an inability to track objects well. When both eyes are affected, the impact on visual development may be substantial.
4.4 Eye redness and swelling
Some children develop redness, pain, or swelling of the eye, particularly when the disease is more advanced. These findings can resemble inflammation or infection, which may delay diagnosis.
4.5 Advanced disease features
Later-stage disease may cause a visibly enlarged eye, glaucoma-like pressure symptoms, or orbital extension. In severe cases, the pupil may be distorted, the eye may become painful, and outward bulging can occur.
5 Diagnosis
Diagnosis combines careful eye examination with imaging and, when appropriate, genetic analysis. Prompt recognition is critical because early treatment improves the chance of preserving both life and vision.
5.1 Clinical examination
Initial assessment includes history, inspection of the eyes, and evaluation of visual behavior. Because children may be too young for standard testing, clinicians often rely on indirect signs and specialized examination under anesthesia.
5.2 Ophthalmoscopy
Ophthalmoscopy allows direct visualization of the retina and can reveal a white or pink tumor mass, associated retinal detachment, or vitreous seeding. It remains a central diagnostic tool and helps define the number, size, and location of lesions.
5.3 Imaging studies
Imaging supports diagnosis, helps assess extent of disease, and assists treatment planning. It is especially valuable for detecting calcification, optic nerve involvement, and spread outside the globe.
5.3.1 Ultrasound
Ultrasound can identify an intraocular mass and often shows internal calcification. It is useful when the retina cannot be fully visualized and can help distinguish retinoblastoma from some other pediatric eye lesions.
5.3.2 MRI
MRI is preferred for evaluating optic nerve invasion, orbital extension, and intracranial involvement. It provides detailed soft-tissue information without radiation exposure.
5.3.3 CT scan
CT can detect calcification well, but it exposes the child to ionizing radiation. For that reason, it is used less often when MRI and ultrasound are available.
5.4 Genetic testing
Testing for RB1 mutations can confirm hereditary risk and guide surveillance of the patient and relatives. It also helps determine whether future children may need early screening.
5.5 Differential diagnosis
Several conditions can mimic retinoblastoma, including Coats disease, persistent fetal vasculature, retinal detachment, and ocular inflammation. Distinguishing among these disorders is important because management differs substantially.
6 Staging and classification systems
Staging describes how far the tumor has progressed, while grouping systems estimate the likelihood of eye salvage and guide therapy. These frameworks are used alongside clinical and imaging findings.
6.1 Intraocular disease
Intraocular disease remains confined to the eye. The main concerns are preserving vision, eradicating the tumor, and preventing local recurrence or extension beyond the globe.
6.2 Extraocular disease
Extraocular disease extends beyond the eye into the orbit or distant tissues. This stage is more serious and often requires intensive multimodal therapy.
6.3 Grouping systems
Grouping systems organize tumors by severity and likelihood of response to eye-sparing treatment. They are especially helpful in comparing similar cases and choosing therapy.
6.3.1 International Classification of Retinoblastoma
The International Classification of Retinoblastoma divides intraocular disease into groups based on tumor size, location, and the presence of vitreous or subretinal seeding. Higher groups indicate more advanced disease and a lower chance of controlling the eye with focal measures alone.
6.3.2 TNM staging
TNM staging describes the primary tumor, regional spread, and distant metastasis. It provides a standardized way to document disease extent, especially in advanced cases.
7 Treatment
Treatment is individualized according to laterality, stage, age, genetic risk, and visual potential. Modern care aims to cure the cancer while preserving as much vision and ocular structure as possible.
7.1 Surgery
Surgery may be recommended when the tumor is too extensive for eye-sparing therapy or when there is concern for spread beyond the eye.
7.1.1 Enucleation
Enucleation is removal of the affected eye and is often used for large, painful, or unsalvageable tumors. When performed appropriately, it can be curative for isolated intraocular disease.
7.1.2 Orbital exenteration
Orbital exenteration removes the eye and surrounding orbital contents. It is rarely required and is generally reserved for extensive extraocular involvement.
7.2 Focal therapies
Focal treatments destroy small localized tumors and are commonly used for selected lesions, either alone or in combination with chemotherapy.
7.2.1 Laser therapy
Laser therapy targets tumor blood supply or directly coagulates small lesions. It is most effective for limited disease.
7.2.2 Cryotherapy
Cryotherapy uses freezing to destroy peripheral tumor foci. It is especially useful for small tumors near the retinal periphery.
7.2.3 Thermotherapy
Thermotherapy applies controlled heat to damage tumor tissue. It may be combined with other approaches to improve local control.
7.3 Chemotherapy
Chemotherapy can shrink tumors, reduce seeding, and make focal therapy more effective. It may be given systemically or delivered directly to the eye.
7.3.1 Systemic chemotherapy
Systemic chemotherapy travels through the bloodstream and can treat both eyes in bilateral disease. It is often used to reduce tumor burden before focal consolidation.
7.3.2 Intra-arterial chemotherapy
Intra-arterial chemotherapy delivers medication directly into the ophthalmic artery. This targeted method can achieve high local drug levels while limiting some systemic exposure.
7.3.3 Intravitreal chemotherapy
Intravitreal chemotherapy is injected into the vitreous cavity to treat persistent vitreous seeding. It requires specialized technique to reduce the risk of tumor escape.
7.4 Radiation therapy
Radiation therapy may be used in selected cases, particularly when other options are insufficient. Because it can increase the risk of later complications and secondary tumors, its use has become more limited.
7.5 Treatment planning by disease extent
Management depends on whether the disease is unilateral or bilateral, confined to the globe, or extraocular. Eye-sparing approaches are favored when feasible, whereas advanced spread usually demands more aggressive therapy.
8 Complications
Complications arise from the disease itself and from its treatment. They may affect vision, ocular structure, and long-term cancer risk.
8.1 Vision loss
Vision loss can result from tumor location, retinal damage, retinal detachment, or treatment-induced scarring. Even when the eye is preserved, functional vision may be reduced.
8.2 Metastasis
Metastatic spread is uncommon in promptly treated cases but can occur when disease extends beyond the eye. Once dissemination develops, the condition becomes significantly more serious.
8.3 Second primary tumors
Individuals with hereditary retinoblastoma have an increased lifetime risk of second cancers, including soft-tissue and bone tumors. This risk is especially notable after radiation exposure.
8.4 Treatment-related adverse effects
Adverse effects may include socket changes after eye removal, dry eye, cataract, retinal injury, or growth disturbances of the orbit in children treated very young. Chemotherapy and radiation can also produce systemic or organ-specific side effects.
9 Prognosis
Outlook depends strongly on the stage at diagnosis and the speed with which treatment begins. Many children do well when disease is detected early and managed in specialized centers.
9.1 Survival rates
Survival is excellent in settings where diagnosis and treatment occur before extraocular spread. Advanced or metastatic disease carries a less favorable prognosis, but outcomes improve with coordinated care.
9.2 Visual outcomes
Visual preservation varies with tumor size, location, and whether one or both eyes are involved. Central tumors and bilateral disease are more likely to affect long-term vision.
9.3 Factors affecting prognosis
Important prognostic factors include extent of disease, optic nerve involvement, seeding, response to therapy, and whether an RB1 mutation is inherited. Delayed diagnosis generally worsens both ocular and survival outcomes.
10 Genetic counseling and screening
Genetic counseling helps families understand inheritance patterns, testing options, and the need for surveillance. It is a routine part of care when hereditary disease is suspected or confirmed.
10.1 Family counseling
Counseling explains the probability of transmission, possible health implications, and recommended monitoring. It also supports informed decisions about future pregnancies and child screening.
10.2 Testing of relatives
Relatives may undergo genetic testing if a familial RB1 change is identified. Clarifying carrier status can identify children who need early ophthalmic evaluation.
10.3 Surveillance of at-risk children
At-risk children are examined at regular intervals beginning in infancy. Early surveillance can detect tumors before symptoms appear, improving the chance of cure and eye preservation.
11 Follow-up and long-term care
Long-term follow-up remains important even after successful treatment. Monitoring addresses recurrence, late effects, visual rehabilitation, and ongoing cancer surveillance.
11.1 Monitoring for recurrence
Regular eye examinations are used to detect tumor recurrence or new lesions. Follow-up is especially important in the first years after treatment, when relapse is more likely.
11.2 Screening for secondary cancers
Patients with hereditary disease may need continued surveillance for second primary malignancies throughout life. This is particularly relevant after prior radiation therapy.
11.3 Rehabilitation and visual support
Rehabilitation may include low-vision aids, educational support, and prosthetic care after eye removal. These measures help children and families adapt to functional and cosmetic changes.
12 Epidemiology
Retinoblastoma is uncommon but well recognized in pediatric oncology and ophthalmology. Its frequency, age at presentation, and pattern of detection vary by region and healthcare access.
12.1 Incidence
The disease is rare worldwide, occurring in a small fraction of childhood cancers. Incidence estimates differ among populations and are influenced by diagnostic resources.
12.2 Age distribution
Most cases are diagnosed in early childhood, often before the age of five. Hereditary disease tends to appear earlier than sporadic unilateral cases.
12.3 Geographic variation
Reported incidence and outcomes vary by country and region, largely because of differences in detection, referral, and treatment availability. Earlier diagnosis is generally associated with better results.
13 History
The history of retinoblastoma reflects progress in pathology, genetics, imaging, and organ-preserving therapy. Over time, management has shifted from primarily surgical removal toward increasingly individualized care.
13.1 Early descriptions
Retinoblastoma was recognized historically as a distinctive pediatric eye tumor because of its white pupillary reflex and rapid progression. Early descriptions laid the groundwork for later clinical classification.
13.2 Advances in diagnosis
The introduction of ophthalmoscopy, imaging, and genetic testing greatly improved diagnostic accuracy. These tools made it possible to identify disease earlier and distinguish it from similar eye conditions.
13.3 Developments in treatment
Treatment evolved from routine eye removal to multimodal care that includes chemotherapy, focal procedures, and targeted delivery methods. Modern approaches place greater emphasis on conserving the eye and useful vision whenever safe and feasible.